Company intelligence / Profile preview

LogicBio Therapeutics

Lexington, Massachusetts, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~62
Development stage: Clinical

Overview

The company's lead product LB-001 for methylmalonic acidemia entered Phase 1/2 clinical trials (SUNRISE) with the first patient dosed in 2021. The trial was designed to assess safety and tolerability in pediatric patients.

Therapeutic areas: Metabolic DisordersRare DiseasesHematology
Modalities: Gene therapyGene editingAAV vectors
Industry: Biotech

Drug pipeline

1 asset

LB-001

Clinical

Indications: Methylmalonic acidemia

Beyond the preview

Go deeper on LogicBio Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LogicBio Therapeutics.

Explore the full profile